These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38634699)

  • 1. Burden of impaired sleep and its improvement through topical treatment in psoriasis and atopic dermatitis.
    Mann C; Dreher M; Rothschmidt JN; Staubach P
    J Dtsch Dermatol Ges; 2024 May; 22(5):655-663. PubMed ID: 38634699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of Itch and Pain on Sleep Quality in Atopic Dermatitis and Psoriasis.
    Kaaz K; Szepietowski JC; Matusiak Ł
    Acta Derm Venereol; 2019 Feb; 99(2):175-180. PubMed ID: 30307027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of dupilumab on sleep disturbances in adult patients with severe atopic dermatitis.
    Milanesi N; Gola M; Cartocci A; Tronconi G; Bruzziches F; Flori ML; Rubegni P; Russo F
    Ital J Dermatol Venerol; 2022 Apr; 157(2):142-145. PubMed ID: 34282867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).
    Silverberg JI; Gooderham MJ; Paller AS; Deleuran M; Bunick CG; Gold LFS; Hijnen D; Calimlim BM; Lee WJ; Teixeira HD; Hu X; Zhang S; Yang Y; Grada A; Platt AM; Thaçi D
    Am J Clin Dermatol; 2024 May; 25(3):485-496. PubMed ID: 38528257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials.
    Reich K; DeLozier AM; Nunes FP; Thyssen JP; Eichenfield LF; Wollenberg A; Ross Terres JA; Watts SD; Chen YF; Simpson EL; Silverberg JI
    J Dermatolog Treat; 2022 May; 33(3):1521-1530. PubMed ID: 33222559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis.
    Silverberg JI; Adam DN; Zirwas M; Kalia S; Gutermuth J; Pinter A; Pink AE; Chiricozzi A; Barbarot S; Mark T; Tindberg AM; Weidinger S
    Am J Clin Dermatol; 2022 Jul; 23(4):547-559. PubMed ID: 35857179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus.
    Kabashima K; Matsumura T; Komazaki H; Kawashima M;
    N Engl J Med; 2020 Jul; 383(2):141-150. PubMed ID: 32640132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvements in itch and sleep following treatment with baricitinib in combination with topical corticosteroids are associated with better quality of life and productivity in adult patients with moderate-to-severe atopic dermatitis: a post hoc analysis from BREEZE-AD7.
    Masuda K; Delozier AM; Kolodsick J; Buchanan A; Pink AE; Sun L; Wang Z; Stingeni L; Thac I D
    Eur J Dermatol; 2022 Apr; 32(2):237-243. PubMed ID: 35866910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel topical agent containing superoxide dismutase 100 000 IU and 4% of plant extracts as a mono-therapy for atopic dermatitis.
    Sgouros D; Katoulis A; Rigopoulos D
    J Cosmet Dermatol; 2018 Dec; 17(6):1069-1072. PubMed ID: 29134748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results.
    Silverberg JI; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Costanzo A; Rosmarin D; Lynde C; Liu J; Gamelli A; Zeng J; Ladizinski B; Chu AD; Reich K
    J Allergy Clin Immunol; 2022 Mar; 149(3):977-987.e14. PubMed ID: 34403658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2.
    Yosipovitch G; Gooderham MJ; Ständer S; Fonacier L; Szepietowski JC; Deleuran M; Girolomoni G; Su JC; Bushmakin AG; Cappelleri JC; Feeney C; Chan G; Thorpe AJ; Valdez H; Biswas P; Rojo R; DiBonaventura M; Myers DE
    Am J Clin Dermatol; 2024 Jan; 25(1):127-138. PubMed ID: 37624488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study.
    Kawashima M; Tango T; Noguchi T; Inagi M; Nakagawa H; Harada S
    Br J Dermatol; 2003 Jun; 148(6):1212-21. PubMed ID: 12828751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and confocal evaluation of avenanthramides-based daily cleansing and emollient cream in pediatric population affected by atopic dermatitis and xerosis.
    Diluvio L; Dattola A; Cannizzaro MV; Franceschini C; Bianchi L
    G Ital Dermatol Venereol; 2019 Feb; 154(1):32-36. PubMed ID: 30207438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the interplay of atopic dermatitis severity with sleep and mental health: a case-control study in adult patients.
    Esposito M; Amicucci G; Salfi F; Pellegrini C; De Berardinis A; Chiricozzi A; Peris K; Tempesta D; Ferrara M; Fargnoli MC
    Postgrad Med; 2024 Jun; 136(5):533-540. PubMed ID: 38864389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS).
    Torrelo A; Rewerska B; Galimberti M; Paller A; Yang CY; Prakash A; Zhu D; Pontes Filho MAG; Wu WS; Eichenfield LF
    Br J Dermatol; 2023 Jul; 189(1):23-32. PubMed ID: 36999560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1.
    Simpson EL; Blauvelt A; Silverberg JI; Cork MJ; Katoh N; Mark T; Schneider SKR; Wollenberg A
    Am J Clin Dermatol; 2024 Jan; 25(1):139-148. PubMed ID: 37804473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histamine and cutaneous nociception: histamine-induced responses in patients with atopic eczema, psoriasis and urticaria.
    Heyer G; Koppert W; Martus P; Handwerker HO
    Acta Derm Venereol; 1998 Mar; 78(2):123-6. PubMed ID: 9534890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
    Beck LA; Thaçi D; Hamilton JD; Graham NM; Bieber T; Rocklin R; Ming JE; Ren H; Kao R; Simpson E; Ardeleanu M; Weinstein SP; Pirozzi G; Guttman-Yassky E; Suárez-Fariñas M; Hager MD; Stahl N; Yancopoulos GD; Radin AR
    N Engl J Med; 2014 Jul; 371(2):130-9. PubMed ID: 25006719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in itch characteristics between psoriasis and atopic dermatitis patients: results of a web-based questionnaire.
    O'Neill JL; Chan YH; Rapp SR; Yosipovitch G
    Acta Derm Venereol; 2011 Sep; 91(5):537-40. PubMed ID: 21533325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of whey associated with dodder seed extract on moderate-to-severe atopic dermatitis in adults: A randomized, double-blind, placebo-controlled clinical trial.
    Mehrbani M; Choopani R; Fekri A; Mehrabani M; Mosaddegh M; Mehrabani M
    J Ethnopharmacol; 2015 Aug; 172():325-32. PubMed ID: 26151244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.